(redirected from amyloid disease)
Also found in: Dictionary, Thesaurus, Medical.
Related to amyloid disease: amyloidosis, Prion diseases


Deposition of amyloid in one or more organs of the body.



or amyloid dystrophy, a disorder of protein metabolism accompanied by the formation within tissues of a specific protein polysaccharide complex known as amyloid. The progress of the disease is associated with distortion of the protein-synthesizing function of the reticuloendothelial system and with accumulation of anomalous proteins in the blood plasma which act as autoantigens and also stimulate the formation of autoantibodies. As a result of antigen-antibody interaction, there is deposition of widely dispersed proteins which figure in the formation of amyloid. Once deposited in tissues, such as vascular and gland walls, the amyloid displaces functionally specialized elements of the organ; this process leads to the destruction of the organ.

Several types of amyloidosis are recognized: primary, secondary, and senile amyloidosis; amyloidosis with multiple myeloma; and localized tumorlike amyloidosis. Primary amyloidosis has no connection with any other disease; it affects mainly the cardiovascular system, alimentary tract, muscles, and skin. Secondary amyloidosis develops subsequent to other diseases which are accompanied by prolonged suppuration and tissue breakdown, such as tuberculosis, syphilis, and rheumatoid arthritis. It most often affects the spleen, liver, kidneys, adrenal glands, and intestines. Senile amyloidosis usually involves the heart. Amyloidosis may be either general or localized. Im-munodepressive and hepatic preparations are used in its treatment.


References in periodicals archive ?
Adlyfe's Vice President of Research and Development, and one of the three inventors, said, "Unlike most diseases, amyloid diseases such as Alzheimer's have long lacked a readily available, fast and accurate detection method to aid diagnosis.
Kirkland, WA; 425-823-6364)was recently issued 2 United States patents pertaining to therapeutics for the treatment of Alzheimer's disease and related disorders, and new non-transgenic animal model screening technologies to identify new therapeutics for amyloid diseases, including Alzheimer's disease.
Recently, he has worked as head of Roche CNS Research on the molecular mechanism of a new kind of antidepressant, a substance P antagonist which modifies a previously untapped neurochemical system, and on new approaches to Amyloid diseases such as Alzheimer's disease.
Neurochem will evaluate the Immtech compounds for activity using proprietary laboratory and animal models of amyloid diseases.
17 /PRNewswire/ -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today that it has appointed Roxanne Duan, Ph.
29 /PRNewswire/ -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today the publication of a study, "Detection of misfolded prion protein in blood with conformationally sensitive peptides," in the August 2007 issue of the journal Transfusion.
The work conducted under the Alzheimer's research program is based on a patent owned by Yissum (the technology transfer company of The Hebrew University of Jerusalem), entitled "Human BChE Variants as Protectors from Amyloid Diseases," which has been licensed to PharmAthene.
Neurochem's patent applications related to the use of some Immtech compounds for treating amyloid diseases such as Alzheimer's.
President & CSO) will fund a 9-month study to further develop a number of novel small molecule therapeutics that ProteoTech scientists have identified as potent inhibitors for a variety of different amyloid diseases, including systemic AA amyloidosis.